Format

Send to

Choose Destination
Oncoimmunology. 2014 Apr 9;3:e28329. eCollection 2014.

Natural killer T cell strategies to combat Epstein-Barr virus infection.

Author information

1
Child and Family Research Institute; Immunity in Health and Disease; University of British Columbia; Vancouver, BC Canada ; Department of Pathology and Laboratory Medicine; University of British Columbia; Vancouver, BC Canada.
2
Child and Family Research Institute; Immunity in Health and Disease; University of British Columbia; Vancouver, BC Canada ; Department of Medical Genetics; University of British Columbia; Vancouver, BC Canada.
3
Child and Family Research Institute; Immunity in Health and Disease; University of British Columbia; Vancouver, BC Canada ; Department of Pathology and Laboratory Medicine; University of British Columbia; Vancouver, BC Canada ; Department of Pathology; Sidra Medical and Research Center; Doha, Qatar.

Abstract

Epstein-Barr virus (EBV) infection results in rapid loss of CD1d expression from the surface of infected B cells, thus enabling the virus to evade immune recognition by natural killer T (NKT) cells. Using pharmacologic means to boost CD1d expression, potent NKT cell effector functions can be elicited toward EBV-infected B cells, suggesting the promise of novel strategies to target EBV-associated diseases such as some B-cell malignancies.

KEYWORDS:

B cell lymphoma; Burkitt's lymphoma; CD1d; Epstein–Barr virus; NKT cells; X-linked lymphoproliferative disease; herpesvirus; immunodeficiency; infection; mononucleosis

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center